In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1368-1376

  Chander, S K ^a   Foster, P A ^a   Leese, M P ^b   Newman, S P ^a   Potter, B V L ^b   Purohit, A ^a   Reed, M J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

2 methoxyoestradiol; Angiogenesis inhibitors; Breast cancer; Matrigel plug assay; Sulphamates

Indexed keywords

2 METHOXY 3 HYDROXY 17BETA CYANOMETHYLESTRA 1,3,5 (10) TRIENE; 2 METHOXY 3 O SULFAMOYL 17BETA CYANOMETHYLESTRA 1,3,5 (10) TRIENE; 2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL 3,17 O,O DISULFAMATE; ANGIOGENESIS INHIBITOR; ESTRADIOL DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; KI 67 ANTIGEN; MATRIGEL; SULFONAMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; ESTRADIOL; FEMALE; HUMANS; LAMININ; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; TRANSPLANTATION, HETEROLOGOUS; TUBULIN MODULATORS;

EID: 34247604099     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603727     Document Type: Article

References (41)

1. Brem S (1998) Angiogenesis antagonists: current clinical trials. Angiogenesis 2: 9-20
2. Brueggemeier RW, Bhat AS, Lovely CJ, Coughenour HD, Joomprabutra S, Weitzel DH, Vandre DD, Yusuf F, Burak Jr WE (2001) 2-Methoxymethylestradiol: a new 2-methoxyestrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol 78: 145-156
3. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38: 2041-2049
4. Dahut WL, Lakani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic agent, in patients with solid tumors. Cancer Biol Ther 5: 271-280
5. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B (1995) Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 55: 395-403
6. Folkman J (1992) The role of angiogenesis in tumour growth. Semin Cancer Biol 3: 65-71
7. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237-239
8. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047
9. Harris AL (1997) Antiangiogenesis for cancer therapy. Lancet 349(Suppl II): 13-15
10. Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LW, Potter BVL, Reed MJ (2003) Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophy Res Commun 305: 909-914
11. Howarth NM, Purohit A, Reed MJ, Potter BVL (1994) Estrone sulfatase: potent inhibitors of estrone sulfamate with therapeutic potential. J Med Chem 37: 219-221
12. Huh JI, Calvo A, Charles R, Green JE (2006) Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression. Cancer Res 66: 3495-3503
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavir F (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
14. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BVL, Reed MJ (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90: 932-937
15. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86
16. Lakhani NJ, Sarkar MA, Venitz J, Figg WD (2003) 2-Methoxyestradiol, a promising anti-cancer agent. Pharmacotherapy 23: 165-172
17. Leese MP, Hejaz HA, Mahon MF, Newman SP, Purohit A, Reed MJ, Potter BVL (2005) A-ring-substituted estrogen-3-O-sulfamates: potent multi-targeted anticancer agents. J Med Chem 48: 5243-5256
18. Leese MP, Leblond B, Smith A et al (2006) 2-Substituted estradiol bis-sulfamates, multi-targeted anti-tumor agents: synthesis, in vitro SAR, protein crystallography and in vivo activity. J Med Chem 49: 7683-7696
19. Liu ZJ, Lee WJ, Zhu BT (2005) Selective insensitivity of ER-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. Cancer Res 65: 5802-5811
20. Liu ZJ, Zhu BT (2004) Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol 88: 265-275
21. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2-ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375
22. MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HAM, Potter BVL, Reed MJ, Packham G (2000) Differential effects of estrone- and estrone-3-O- sulfamate derivatives on mitotic arrest, apoptosis and microtubule assemble in human breast cancer cells. Cancer Res 60: 5441-5450
23. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR (1991) A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88: 9026-9030
24. Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, Leese MP, Potter BVL, Reed MJ, Purohit A (2006) The role of 17β-hydroxysteroid dehydrogenase in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 66: 324-330
25. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, Potter BVL, Reed MJ (2004) Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethylestrogen sulfamates. Int J Cancer 109: 533-540
26. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab Invest 67: 519-528
27. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (Fetal Liver Kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218
28. Purohit A, William GJ, Roberts CJ, Potter BVL, Reed MJ (1995a) In vivo inhibition of oestrone sulphatase and dehydroepi-androsterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 63: 106-111
29. Purohit A, Williams GJ, Howarth NM, Potter BVL, Reed MJ (1995b) Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry 34: 11508-11514
30. Raobaikady B, Purohit A, Chander SK, Lawrence LW, Leese MP, Potter BVL, Reed MJ (2003) Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 84: 351-358
31. Raobaikady B, Reed MJ, Leese MP, Potter BVL, Purohit A (2005) Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2 substituted oestradiol mono-and bis-3-O-sulphamates. Int J Cancer 117: 150-159
32. Seegers JC, Avelin ML, Van Aswegan CH, Cross M, Koch F, Joubert WS (1989) The cytotoxic effects of estradiol-17β, catecholestradiols and methoxyestradiols on dividing MCF-7 and Hela cells. J Steroid Biochem 32: 797-809
33. Terman BI, Dougher-Vermazen M, Carrison ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586
34. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN, Mooberry SL (2003) Novel 2-methoxyestradiol analogs within antitumor activity. Cancer Res 63: 1538-1549
35. Utsumi T, Leese MP, Chander SK, Gaukroger K, Purohit A, Newman SP, Potter BVL, Reed MJ (2005) The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J Steroid Biochem Mol Biol 94: 219-227
36. Vacca A, Lurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F (1999) Antiangiogenesis is produced by non-toxic doses of vinblastine. Blood 94: 4143-4155
37. Vicker N, Ho YT, Robinson JJ, Woo LW, Purohit A, Reed MJ, Potter BVL (2003) Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg Med Chem Lett 13: 863-865
38. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10
39. Zhang HT, Harris AL (1998) Anti-angiogenic therapies in cancer clinical trials. Expert Opin Investig Drugs 7: 1629-1655
40. Zhu BT, Conney AH (1998a) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19: 1-27
41. Zhu BT, Conney AH (1998b) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58: 2269-2277